Last reviewed · How we verify
M-M-R II vaccine
M-M-R II vaccine is a Live attenuated vaccine Biologic drug developed by Sanofi. It is currently in Phase 3 development for Prevention of measles, mumps, and rubella in children and adults. Also known as: M-M-R™ II, M-M-R® II.
M-M-R II is a live attenuated vaccine that stimulates the immune system to produce antibodies and cellular immunity against measles, mumps, and rubella viruses.
M-M-R II is a live attenuated vaccine that stimulates the immune system to produce antibodies and cellular immunity against measles, mumps, and rubella viruses. Used for Prevention of measles, mumps, and rubella in children and adults.
At a glance
| Generic name | M-M-R II vaccine |
|---|---|
| Also known as | M-M-R™ II, M-M-R® II |
| Sponsor | Sanofi |
| Drug class | Live attenuated vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains weakened (attenuated) strains of measles, mumps, and rubella viruses that replicate in the body without causing disease. This replication triggers both humoral (antibody) and cell-mediated immune responses, providing long-term protection against infection with wild-type viruses. The vaccine is typically administered as two doses to achieve optimal immunity.
Approved indications
- Prevention of measles, mumps, and rubella in children and adults
Common side effects
- Injection site reactions (pain, redness, swelling)
- Fever
- Rash
- Parotitis (mumps-like symptoms)
- Arthralgia or arthritis
Key clinical trials
- Live Vaccines and Innate Immune Training in COPD. (PHASE4)
- Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?
- A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population (PHASE3)
- Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age (PHASE3)
- Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- M-M-R II vaccine CI brief — competitive landscape report
- M-M-R II vaccine updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about M-M-R II vaccine
What is M-M-R II vaccine?
How does M-M-R II vaccine work?
What is M-M-R II vaccine used for?
Who makes M-M-R II vaccine?
Is M-M-R II vaccine also known as anything else?
What drug class is M-M-R II vaccine in?
What development phase is M-M-R II vaccine in?
What are the side effects of M-M-R II vaccine?
Related
- Drug class: All Live attenuated vaccine drugs
- Manufacturer: Sanofi — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Prevention of measles, mumps, and rubella in children and adults
- Also known as: M-M-R™ II, M-M-R® II
- Compare: M-M-R II vaccine vs similar drugs
- Pricing: M-M-R II vaccine cost, discount & access